Investor Relations

Corporate Profile

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.

Press Releases

Dec 20, 2018
Autolus Therapeutics to Join NASDAQ Biotechnology Index
LONDON , Dec. 20, 2018 /PRNewswire/ --  Autolus Therapeutics plc  (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI) as part of the


More events are coming soon.